Review Highlights Multiple Compounds' Anti-Aging and Cancer-Preventive Effects in Mice
Background
Aging is a complex process characterized by progressive decline in physiological functions, often leading to increased susceptibility to diseases like cancer. Identifying substances that can mitigate age-related changes and inhibit tumor development is a significant area of research. This review synthesizes findings from various experimental studies to evaluate the geroprotective and anti-carcinogenic potential of several natural and synthetic compounds.
Results
Across the reviewed experimental studies, the tested compounds consistently inhibited age-related alterations and spontaneous tumor development, alongside extending the life span of various mouse strains. Specifically, Melatonin, Epitalon, Deltaran, Aqualen, and Neuronol each demonstrated significant geroprotective effects. The observed benefits, including the inhibition of age-related changes in estrus function and a reduction in spontaneous tumor incidence, were found to be influenced by the specific dose and administration regimen. Furthermore, the genetic background of the mouse strain played a crucial role in the efficacy of these interventions. The review consistently showed that these diverse compounds extended the life span and inhibited spontaneous tumor development across multiple genetically distinct mouse models.
Why It Matters
This review highlights the significant potential of various compounds, from natural hormones like Melatonin to synthetic peptides like Epitalon, as geroprotective and anti-carcinogenic agents. The consistent observation of life span extension and tumor inhibition in diverse mouse models suggests a broad applicability for these substances in mitigating age-related pathologies. This foundational work could pave the way for future clinical trials investigating these compounds for human anti-aging and cancer prevention strategies, potentially leading to novel therapeutic interventions. Further research, including detailed mechanistic studies and dose-response analyses in larger animal cohorts, is warranted before progressing to human Phase I or Phase II trials.